Found: 47
Select item for more details and to access through your institution.
Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 940, doi. 10.1002/cpdd.904
- By:
- Publication type:
- Article
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 107, doi. 10.1002/cpdd.575
- By:
- Publication type:
- Article
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
- By:
- Publication type:
- Article
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
- By:
- Publication type:
- Article
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25904-w
- By:
- Publication type:
- Article
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
- Published in:
- Nature Medicine, 2011, v. 17, n. 7, p. 875, doi. 10.1038/nm.2377
- By:
- Publication type:
- Article
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1604, doi. 10.1007/s10637-021-01145-y
- By:
- Publication type:
- Article
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 1, p. 163, doi. 10.1007/s10637-020-00975-6
- By:
- Publication type:
- Article
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3
- By:
- Publication type:
- Article
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 2, p. 419, doi. 10.1007/s10637-019-00776-6
- By:
- Publication type:
- Article
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 738, doi. 10.1007/s10637-019-00768-6
- By:
- Publication type:
- Article
Retraction Note: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma.
- Published in:
- PLoS ONE, 2014, v. 9, n. 3, p. 1, doi. 10.1371/journal.pone.0090353
- By:
- Publication type:
- Article
Early Detection of Erlotinib Treatment Response in NSCLC by 3'-Deoxy-3'-[<sup>18</sup>F]-Fluoro-L-Thymidine ([<sup>18</sup>F]FLT) Positron Emission Tomography (PET).
- Published in:
- PLoS ONE, 2008, v. 3, n. 12, p. 1, doi. 10.1371/journal.pone.0003908
- By:
- Publication type:
- Article
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2991, doi. 10.1007/s00262-021-02910-x
- By:
- Publication type:
- Article
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkz094
- By:
- Publication type:
- Article
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00406-0
- By:
- Publication type:
- Article
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 3, p. 1291, doi. 10.1111/bcp.14508
- By:
- Publication type:
- Article
Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.
- Published in:
- Oncogene, 2005, v. 24, n. 10, p. 1683, doi. 10.1038/sj.onc.1208375
- By:
- Publication type:
- Article
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.
- Published in:
- Cancers, 2022, v. 14, n. 17, p. 4079, doi. 10.3390/cancers14174079
- By:
- Publication type:
- Article
Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2580, doi. 10.3390/cancers14112580
- By:
- Publication type:
- Article
Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
- Published in:
- Frontiers in Oncology, 2022, v. 11, p. 1, doi. 10.3389/fonc.2021.786120
- By:
- Publication type:
- Article
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.
- Published in:
- Oncogene, 1999, v. 18, n. 1, p. 67, doi. 10.1038/sj.onc.1202273
- By:
- Publication type:
- Article
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.
- Published in:
- Breast Care, 2016, v. 11, n. 3, p. 167, doi. 10.1159/000447284
- By:
- Publication type:
- Article
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 6, p. 815, doi. 10.1007/s00280-020-04176-z
- By:
- Publication type:
- Article
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 9, p. 1159, doi. 10.1002/jcph.902
- By:
- Publication type:
- Article
The Evolving Role of Cyclin-Dependent Kinase Inhibitors in Cancer Management.
- Published in:
- Clinical Advances in Hematology & Oncology, 2017, v. 15, n. 3, p. 174
- By:
- Publication type:
- Article
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 1, p. 105, doi. 10.1007/s11523-022-00931-9
- By:
- Publication type:
- Article
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 16, p. 3043, doi. 10.1002/cncr.28120
- By:
- Publication type:
- Article
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00471-5
- By:
- Publication type:
- Article
Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.
- Published in:
- Oncologist, 2018, v. 23, n. 7, p. 814, doi. 10.1634/theoncologist.2017-0552
- By:
- Publication type:
- Article
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
- Published in:
- Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325
- By:
- Publication type:
- Article
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
- Published in:
- Oncologist, 2018, v. 23, n. 4, p. 401, doi. 10.1634/theoncologist.2017-0691
- By:
- Publication type:
- Article
Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 12, p. 1904, doi. 10.1002/cncr.34730
- By:
- Publication type:
- Article
Evaluation of statistical designs in phase I expansion cohorts: the dana-farber/harvard cancer center experience.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 7, p. 1, doi. 10.1093/jnci/dju163
- By:
- Publication type:
- Article
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-16344-z
- By:
- Publication type:
- Article
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-15315-8
- By:
- Publication type:
- Article